Medicare Finalizes Coverage for CareDx Transplant Tests, Shares Surge 35%
CDNA has more than doubled off its 52-week low of $10.96 on elevated volume (5.0× avg).
Summary
Medicare finalized its Local Coverage Determination (LCD) for molecular testing of solid organ allograft rejection, confirming coverage for CareDx's entire transplant surveillance portfolio—AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. The policy takes effect August 30, 2026, and removes a major reimbursement overhang. Shares jumped 35.6% to $40.34, near the 52-week high of $40.38. This follows the Q1 earnings beat and Naveris acquisition, and the recent sale of the Lab Products division for $170M. The coverage decision locks in a key revenue driver across kidney, heart, and lung transplant monitoring. Q2 earnings on July 30 will be the next catalyst to watch for updated guidance incorporating this policy.
At the time of this announcement, CDNA was trading at $39.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $10.96 to $40.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: dpa-AFX.